Disclosure Of NDA Filings Recommended In Transparency Report
• By The Tan Sheet
Firms may have to marshal legal arguments to prevent public disclosure of drug development milestones, including OTC switch filings, following the FDA Transparency Task Force's recommendation that the agency disclose when applications are submitted and withdrawn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
